SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Machine learning models for predicting response to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer brain metastases: a systematic review and meta-analysis.
Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPredicting clinical and radiological outcomes of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung cancer (NSCLC) and brain metastases (BMs) is crucial for effective patient management. Machine learning (ML)-based models have increasingly been utilized to predict EGFR-TKI response in patients with lung cancer brain metastasis (LCBM). In this study, we aimed to evaluate the predictive performance of ML-based models for EGFR-TKI response prediction.
methodsA comprehensive literature search was conducted using PubMed, Embase, Scopus, and Web of Science from database inception to April 25, 2025. Studies that developed ML-based models to predict EGFR-TKI response were included.
resultsEight studies involving 1322 LCBM patients were included. The included studies used logistic regression (LR), LR with least absolute shrinkage and selection operator (LASSO), decision tree (DT), and a Cox-based deep learning model (DL-Cox). The meta-analysis revealed a pooled area under the curve (AUC) of 0.84 (95% CI 0.78-0.91) and accuracy (ACC) of 0.75 (95% CI 0.62-0.88) with a sensitivity (SEN) of 0.82 (95% CI 0.77-0.87) and a specificity (SPE) of 0.73 (95% CI 0.66-0.80) for prediction of EGFR-TKI response. The meta-analysis of diagnostic odds ratios (DOR) exhibited a pooled DOR of 12.41 (95% CI 7.32-21.04).
conclusionsML-based models show promising ability to predict EGFR-TKI response in LCBM, supporting their potential to guide treatment selection. However, their use in clinical practice remains limited by small retrospective datasets and lack of external validation.
Indexed as
Identifiers
41335187What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.